NASDAQ NMS - GLOBAL MARKET · GALT
+0.44% · +$0.0200 · Vol 270.9K
Market closed · last close 4:00 PM ET · price as of 16:50:53 ET
Galectin Therapeutics Inc

Galectin Therapeutics Inc

Biotechnology
$3.64
Card
Relationship Map

Follow $GALT

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $GALT by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
GALT
Galectin Therapeutics Inc
Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Lowest range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

25/ 100
Veridion Score
Lowest range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is GALT moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading GALT catalysts
About Galectin Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2002
Employees
9
Country
US

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$3.62
Day high
$3.69
Day low
$3.51
Previous close
$3.62
52W high
$6.51
-44.15% from high
52W low
$2.08
35% of range
Market cap
$365.1M
EPS
$-0.4275
Beta
-0.28
Shares out
100.8M
Volume
270.9K
0.89× rel vol
Avg volume
305.1K
VWAP
$3.62
Price history computed in-house
1W
-6.77%
1M
-10.22%
3M
-10.45%
1Y
-23.45%
YTD
-12.60%
SMA 50 $3.74 · below
SMA 200 $3.22 · above
52W position 35%

GALT overview

Veridion Score
25
Registered · 2026-10-08
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around GALT.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading GALT Form 4 filings
Public disclosures

Congress activity in GALT

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

GALT contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GALT in this window.
Lobbying spend

GALT lobbying filings, year to date.

Registered lobbying filings matched to Galectin Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GALT in this window.
Loading news for GALT
Analyst ratings
Sovereign unlock shows live analyst consensus for GALT.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.